Table 3.
Mechanisms of priming the immune system by the different vaccines
| Vaccine typea | Percentages of cells in PEC after vaccinationb | ||||
|---|---|---|---|---|---|
| NK | PMNs | CD11b+ (MØ) | CD11c+IAk+ (DCm) | CD11c+Ly6C+ (DCi) | |
| NV | 10 ± 0.01 | 13 ± 0.01 | 75 ± 0.06 | 3 ± 0.04 | 7 ± 0.05 |
| BM-DM/LM | 5 ± 0.02 | 9 ± 0.02 | 5 ± 0.01 | 55 ± 0.05 | 45 ± 0.03 |
| BM-DM-IFN/LM | 5 ± 0.02 | 7 ± 0.03 | 5 ± 0.02 | 70 ± 0.03 | 25 ± 0.02 |
| ENDO/LLO | 2 ± 0.01 | 5 ± 0.01 | 30 ± 0.03 | 7 ± 0.05 | 20 ± 0.03 |
| ENDO-IFN/LLO | 3 ± 0.02 | 5 ± 0.02 | 45 ± 0.05 | 27 ± 0.02 | 25 ± 0.05 |
CBA/J mice were vaccinated i.p or not (NV) with 30 µg of LLO loaded endosomes from resting BM-DM (ENDO/LLO), LLO loaded endosomes from IFN-γ activated BM-DM (ENDO-IFN/LLO), LM infected resting BM-DM (1 × 106 cells) or LM infected and IFN-γ activated BM-DM (1 × 106 cells) for 7 days (n = 5/vaccination type). Next, mice were inoculated with LM (5 × 103 bc/mice) for 3 days.
PEC were obtained after 2-fold ice-cold washings with Hank´s balanced buffer and surface stained with the following FITC or PE-labelled antibodies: CD11b (MØ), CD11c (DC). Next, PE-CD11c+ cells were analyzed for the percentages of APC-labelled Ly6C or 40F anti-IAk antibodies to distinguish for mature DC (DCm) (CD11c+IAk+) or immature DC (CD11c+Ly6C+). Samples were acquired using FACSCanto flow cytometer and percentages of positive cells for each antibody are shown. Results are expressed as the mean ± SD of triplicates (p<0.05).